02/2024. MV140 for recurrent urinary tract infections

Results of the first North American study with MV140 published in the Canadian Urological Association Journal.

This study evaluated the number of infections in women with recurrent urinary tract infections (UTIs) over 9 months after 3 months of treatment with MV140 (Uromune). The results show a 75% reduction compared to the previous year and an improvement in quality of life.

The study was conducted at the Department of Urology at Queen’s University (Kingston, Canada) and is the first study of MV140 in North America.

MV140 is a sublingual mucosal vaccine developed by INMUNOTEK for the prevention of UTIs that contains the key bacteria responsible for these infections.

+ info